Recently, Pembrolizumab revealed a significant superiority over platinum based chemotherapy as first-line treatment of non-oncogene addicted NSCLC patients whose tumors overexpressed PD-L1>50% [12], becoming the new backbone in this subgroup of patients who represent about 30% of the overall untreated population. The gene discussed is CD274; the disease is non-small cell lung carcinoma.